Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir PET Signal and Cognitive Change in Early AD
NCT03901105Phase 3Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Risk Ratio for AD Symptom Progression on CDR-SB at 18 months. Started Mar 2019; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03901105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901105.